Rebecca joined AMV in 2010 and brought 15 years of experience in finance. She is responsible for accounting, finance and investor relations.
Prior to AMV, Rebecca was Director of Finance at CV Therapeutics (“CVT”) until the acquisition of the company by Gilead Sciences in 2009 for $1.4B. At CVT, she oversaw the financial planning function for the company’s Commercial organization, which had a $120M operating budget and 270 employees. Prior to CVT, Rebecca was CFO at CareandHealth in the UK where she managed all finance, legal, HR, and operational functions of the firm. Previously, Rebecca was Director of Investor Relations at Chiron Corporation until its acquisition by Novartis in 2006 at a value of $8.8B. She began her career at Deloitte where she progressed through various positions in audit and financial consulting, most recently as a Senior Manager in the Financial Advisory Services group.
Rebecca has an MBA from Kellogg School of Management, a Chartered Financial Analyst designation, and in 1997 she earned a Canadian Chartered Accountant designation.